AZN

AstraZeneca Plc secures EU approval for fixed-term CLL regimen

AstraZeneca's Calquence, combined with venetoclax, has received EU approval for treating untreated chronic lymphocytic leukaemia, showing promising trial results...

AstraZeneca Plc Imfinzi recommended for EU approval in bladder cancer

AstraZeneca's Imfinzi gains EU approval for treating muscle-invasive bladder cancer, offering a promising neoadjuvant and adjuvant therapy based on pivotal trial results...

AstraZeneca Plc acquires EsoBiotec in $1bn cell therapy deal

AstraZeneca has successfully acquired EsoBiotec, enhancing its cancer therapy capabilities with innovative in vivo cell therapies that promise faster treatment access...

AstraZeneca’s Imfinzi improves disease-free survival in high-risk NMIBC

AstraZeneca's Imfinzi shows promise in improving disease-free survival for high-risk non-muscle-invasive bladder cancer, as highlighted by recent POTOMAC trial results...

AstraZeneca Plc Calquence combo approved in EU for first-line MCL

AstraZeneca’s Calquence, combined with bendamustine and rituximab, is now EU approved for untreated mantle cell lymphoma, offering a significant survival advantage...

AstraZeneca Plc Breztri succeeds in Phase III asthma trials

AstraZeneca's Breztri has shown significant promise in treating uncontrolled asthma, meeting primary endpoints in the KALOS and LOGOS Phase III trials...

AstraZeneca Plc reports revenue up 10%, strong pipeline progress

AstraZeneca Plc's Q1 2025 results reveal strong growth and a focus on pipeline delivery, setting the stage for ambitious goals leading to 2030...

AstraZeneca Plc Enhertu trial hits key PFS goal

The DESTINY-Breast09 Phase III trial of Enhertu marks a breakthrough for HER2-positive metastatic breast cancer, showcasing superior efficacy over traditional therapies...

AstraZeneca Plc Enhertu approved in the EU for HER2 breast cancer

AstraZeneca and Daiichi Sankyo's Enhertu gains EU approval for treating HR-positive, HER2-low metastatic breast cancer, offering new hope for patients...

AstraZeneca’s Imfinzi granted FDA approval in the US for bladder cancer

AstraZeneca's Imfinzi has received FDA approval as a groundbreaking treatment for muscle-invasive bladder cancer, significantly improving patient outcomes in clinical trials...

AstraZeneca Plc advances cell therapy ambition, acquiring EsoBiotec

AstraZeneca is set to transform cancer treatment by acquiring EsoBiotec, a leader in in vivo cell therapies that promise quicker, more effective patient care...

AstraZeneca Plc Imfinzi demonstrates improved EFS in early stage gastric cancer

The MATTERHORN Phase III trial reveals promising results for AstraZeneca's Imfinzi in enhancing event-free survival for patients with early-stage gastric cancer...

AstraZeneca Plc Datroway approved in the US for metastatic breast cancer

AstraZeneca and Daiichi Sankyo's Datroway gains FDA approval, offering a new treatment option for specific metastatic breast cancer cases...

AstraZeneca’s Tagrisso approved in the EU for patients with unresectable NSCLC

AstraZeneca's Tagrisso gains EU approval for treating advanced NSCLC, showing significant efficacy in reducing disease progression in key trials...

AstraZeneca Plc Imfinzi approved in the US for limited-stage SCLC

AstraZeneca's Imfinzi receives FDA approval for limited-stage small cell lung cancer, marking a significant breakthrough in extending patient survival...
Search

Funds

AZN

AstraZeneca Plc secures EU approval for fixed-term CLL regimen

AstraZeneca's Calquence, combined with venetoclax, has received EU approval for treating untreated chronic lymphocytic leukaemia, showing promising trial results...

AstraZeneca Plc Imfinzi recommended for EU approval in bladder cancer

AstraZeneca's Imfinzi gains EU approval for treating muscle-invasive bladder cancer, offering a promising neoadjuvant and adjuvant therapy based on pivotal trial results...

AstraZeneca Plc acquires EsoBiotec in $1bn cell therapy deal

AstraZeneca has successfully acquired EsoBiotec, enhancing its cancer therapy capabilities with innovative in vivo cell therapies that promise faster treatment access...

AstraZeneca’s Imfinzi improves disease-free survival in high-risk NMIBC

AstraZeneca's Imfinzi shows promise in improving disease-free survival for high-risk non-muscle-invasive bladder cancer, as highlighted by recent POTOMAC trial results...

AstraZeneca Plc Calquence combo approved in EU for first-line MCL

AstraZeneca’s Calquence, combined with bendamustine and rituximab, is now EU approved for untreated mantle cell lymphoma, offering a significant survival advantage...

AstraZeneca Plc Breztri succeeds in Phase III asthma trials

AstraZeneca's Breztri has shown significant promise in treating uncontrolled asthma, meeting primary endpoints in the KALOS and LOGOS Phase III trials...

AstraZeneca Plc reports revenue up 10%, strong pipeline progress

AstraZeneca Plc's Q1 2025 results reveal strong growth and a focus on pipeline delivery, setting the stage for ambitious goals leading to 2030...

AstraZeneca Plc Enhertu trial hits key PFS goal

The DESTINY-Breast09 Phase III trial of Enhertu marks a breakthrough for HER2-positive metastatic breast cancer, showcasing superior efficacy over traditional therapies...

AstraZeneca Plc Enhertu approved in the EU for HER2 breast cancer

AstraZeneca and Daiichi Sankyo's Enhertu gains EU approval for treating HR-positive, HER2-low metastatic breast cancer, offering new hope for patients...

AstraZeneca’s Imfinzi granted FDA approval in the US for bladder cancer

AstraZeneca's Imfinzi has received FDA approval as a groundbreaking treatment for muscle-invasive bladder cancer, significantly improving patient outcomes in clinical trials...

AstraZeneca Plc advances cell therapy ambition, acquiring EsoBiotec

AstraZeneca is set to transform cancer treatment by acquiring EsoBiotec, a leader in in vivo cell therapies that promise quicker, more effective patient care...

AstraZeneca Plc Imfinzi demonstrates improved EFS in early stage gastric cancer

The MATTERHORN Phase III trial reveals promising results for AstraZeneca's Imfinzi in enhancing event-free survival for patients with early-stage gastric cancer...

AstraZeneca Plc Datroway approved in the US for metastatic breast cancer

AstraZeneca and Daiichi Sankyo's Datroway gains FDA approval, offering a new treatment option for specific metastatic breast cancer cases...

AstraZeneca’s Tagrisso approved in the EU for patients with unresectable NSCLC

AstraZeneca's Tagrisso gains EU approval for treating advanced NSCLC, showing significant efficacy in reducing disease progression in key trials...

AstraZeneca Plc Imfinzi approved in the US for limited-stage SCLC

AstraZeneca's Imfinzi receives FDA approval for limited-stage small cell lung cancer, marking a significant breakthrough in extending patient survival...
Search

Funds

AZN

FTSE 100

Funds